Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.55 |
| ▸ | CDK9 | P50750 | 3/20 | 0.49 |
| ▸ | FEN1 | P39748 | 5/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28503231 | 0.91 | JAK1 (0.56) | JAK1CDK9CCNT1PIK3CABRD4 | |
| SCHEMBL15561004 | 0.82 | GRM5 (0.47) | JAK1CDK9CCNT1BRD4GRM5 | |
| SCHEMBL1199494 | 0.79 | GRM5 (0.55) | CDK9CCNT1GRM5GRM1PDK4 | |
| SCHEMBL13993111 | 0.78 | GRM1 (0.57) | JAK1CDK9CCNT1GRM5GRM1 | |
| SCHEMBL15556267 | 0.78 | JAK1 (0.49) | JAK1FEN1ALOX5APPIK3CA | |
| SCHEMBL30659278 | 0.78 | JAK1 (0.54) | JAK1CDK9CCNT1BRD4GRM5 | |
| SCHEMBL31442803 | 0.78 | JAK1 (0.54) | JAK1CDK9CCNT1BRD4GRM5 | |
| SCHEMBL15778894 | 0.78 | NR1H2 (0.53) | JAK1PIK3CA | |
| SCHEMBL15778686 | 0.78 | ESR2 (0.54) | JAK1PIK3CA | |
| SCHEMBL28499853 | 0.78 | PLK4 (0.45) | JAK1CDK9FEN1ALOX5APCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
| EP-2867233-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014006554-A1 | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | JAK1 83/4885CDK9 284/4885FEN1 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.